Ibnsina Pharma’s consolidated profits surge 134% YoY in 9 months
Updated 11/7/2024 1:16:00 AM
Arab Finance: Ibnsina Pharma (ISPH) recorded a 133.57% year-on-year (YoY) increase in consolidated net profits after tax and non-controlling interest in the first nine months of 2024 to EGP 406.513 million, versus EGP 174.037 million, the firm disclosed.
Net sales came in at EGP 38.402 billion in the January-September period this year, up from EGP 23.805 billion in the same period last year.
The company’s standalone net profits after tax stood at EGP 415.708 million in the nine-month period, rising from EGP 202.98 million in the corresponding period a year ago.
Meanwhile, standalone net sales increased to EGP 38.271 billion from EGP 23.729 billion.
Established in 2001, Ibnsina Pharma is the second-largest pharmaceutical distributor in Egypt, distributing products from over 350 global and local companies to more than 46,000 customers of pharmacies, hospitals, wholesalers, and healthcare institutions.
Related News
